2009 Press Releases

Onyx Pharmaceuticals Announces Webcast to Discuss Multiple Myeloma Market and Carfilzomib Clinical Overview

Webcast to Take Place at 11:00 a.m. ET Today, October 12

Emeryville, CA. — Oct. 12, 2009

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast, led by external medical experts, to discuss the multiple myeloma market and provide an overview of the carfilzomib clinical program. The webcast will take place today at 11:00 a.m. ET, and can be accessed at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar  

The event follows the announcement of Onyx’s intention to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix’s lead compound, carfilzomib, is a next generation proteasome inhibitor that is currently in multiple clinical trials, including an advanced Phase 2b clinical trial for patients with relapsed and refractory multiple myeloma.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.  

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.